A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Inavolisib
DRUG: Placebo
DRUG: CDK4/6i
DRUG: Letrozole

Sponsor

Hoffmann-La Roche